VYNE Therapeutics Inc (VYNE)
2.79
+0.09
(+3.33%)
USD |
NASDAQ |
May 17, 16:00
2.79
0.00 (0.00%)
After-Hours: 20:00
VYNE Therapeutics Enterprise Value: -45.71M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -45.71M |
| May 16, 2024 | -46.72M |
| May 15, 2024 | -45.85M |
| May 14, 2024 | -43.96M |
| May 13, 2024 | -44.84M |
| May 10, 2024 | -47.16M |
| May 09, 2024 | -47.45M |
| May 08, 2024 | -46.43M |
| May 07, 2024 | -43.96M |
| May 06, 2024 | -46.58M |
| May 03, 2024 | -47.89M |
| May 02, 2024 | -49.63M |
| May 01, 2024 | -49.77M |
| April 30, 2024 | -49.91M |
| April 29, 2024 | -48.34M |
| April 26, 2024 | -50.20M |
| April 25, 2024 | -50.62M |
| April 24, 2024 | -49.19M |
| April 23, 2024 | -52.77M |
| April 22, 2024 | -52.34M |
| April 19, 2024 | -53.77M |
| April 18, 2024 | -53.06M |
| April 17, 2024 | -51.63M |
| April 16, 2024 | -51.34M |
| April 15, 2024 | -49.19M |
| Date | Value |
|---|---|
| April 12, 2024 | -46.33M |
| April 11, 2024 | -43.04M |
| April 10, 2024 | -47.62M |
| April 09, 2024 | -46.48M |
| April 08, 2024 | -46.76M |
| April 05, 2024 | -45.48M |
| April 04, 2024 | -45.33M |
| April 03, 2024 | -41.61M |
| April 02, 2024 | -42.76M |
| April 01, 2024 | -41.90M |
| March 31, 2024 | -42.04M |
| March 28, 2024 | -49.97M |
| March 27, 2024 | -51.52M |
| March 26, 2024 | -53.35M |
| March 25, 2024 | -58.43M |
| March 22, 2024 | -59.13M |
| March 21, 2024 | -60.40M |
| March 20, 2024 | -62.52M |
| March 19, 2024 | -63.79M |
| March 18, 2024 | -66.18M |
| March 15, 2024 | -64.91M |
| March 14, 2024 | -64.21M |
| March 13, 2024 | -64.21M |
| March 12, 2024 | -63.65M |
| March 11, 2024 | -63.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.14M
Minimum
Jan 31 2024
624.52M
Maximum
Feb 09 2021
56.95M
Average
6.626M
Median
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 6.425B |
| AN2 Therapeutics Inc | -46.50M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.249M |
| Revenue (Quarterly) | 0.098M |
| Total Expenses (Quarterly) | 7.478M |
| EPS Diluted (Quarterly) | -0.15 |
| Profit Margin (Quarterly) | -6.38K% |
| Earnings Yield | -205.4% |
| Normalized Earnings Yield | -199.15 |